Shield Therapeutics plc (LON:STX – Get Free Report) shares rose 11.4% on Thursday . The stock traded as high as GBX 5.20 and last traded at GBX 4.90. 7,737,915 shares changed hands during mid-day trading, an increase of 242% from the average session volume of 2,261,929 shares. The stock had previously closed at GBX 4.40.
Shield Therapeutics Stock Performance
The stock’s 50 day simple moving average is GBX 5.51 and its two-hundred day simple moving average is GBX 7.30. The company has a market capitalization of £52.51 million, a P/E ratio of -2.46 and a beta of 1.72. The company has a debt-to-equity ratio of -146.28, a current ratio of 0.75 and a quick ratio of 2.16.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
